NCT02163720 is a clinical trial of Yondelis®-Caelyx® in Ovarian Cancer, sponsored by ARCAGY/ GINECO GROUP.

Who is sponsoring NCT02163720?

NCT02163720 is sponsored by ARCAGY/ GINECO GROUP.

What drugs are being tested in NCT02163720?

Interventions in NCT02163720: Yondelis®-Caelyx®.

What condition does NCT02163720 study?

NCT02163720 studies Ovarian Cancer.

Is NCT02163720 still recruiting?

NCT02163720 is currently completed. Last updated 28 September 2020.

Last reviewed 2020-09-28 · How we verify

NCT02163720

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non Interventional Study Dealing With the Use of Trabectedin (Yondelis®)-Pegylated Liposomal Doxorubicin (Caelyx®) in Patient With Platinum-sensitive Relapse

Completed Last updated 28 September 2020

What this trial tests

trial testing Yondelis®-Caelyx® in Ovarian Cancer in 101 participants. Completed in 18 September 2018.

Timeline

10 July 2014

Primary endpoint
1 March 2017

18 September 2018

Quick facts

Lead sponsor	ARCAGY/ GINECO GROUP
Status	Completed
Study type	OBSERVATIONAL
Enrollment	101
Start date	10 July 2014
Primary completion	1 March 2017
Estimated completion	18 September 2018
Sites	33 locations across France

Drugs / interventions tested

Yondelis®-Caelyx® — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

ARCAGY/ GINECO GROUP — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Evaluate the proportion of patient partially versus fully platinum-sensitive in relapse ovarian cancer
Time frame: Patient will be followed during 12 months
To assess patient safety and the tolerance of Yondelis®-Caelyx® administered regarding the daily practice of the oncologist.

Sponsor's own description

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®, in ovarian platinum sensitive cancer relapse.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications.
Sedighzadeh SS, Khoshbin AP, Razi S, Keshavarz-Fathi M, et al · · 2021 · cited 160× · PMID 34012800 · DOI 10.21037/tlcr-20-1241
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective.
Tenchov R, Sasso JM, Zhou QA. · · 2023 · cited 159× · PMID 37162501 · DOI 10.1021/acs.bioconjchem.3c00174
Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.
Gralewska P, Gajek A, Marczak A, Rogalska A. · · 2024 · cited 21× · PMID 39125873 · DOI 10.3390/ijms25158304
Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials.
Li C, Qiao S, Kang M, Gao X, et al · · 2023 · cited 3× · PMID 38186978

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other ARCAGY/ GINECO GROUP trials

Trials by the same sponsor.

NCT06715241 — A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY · Phase 2 · active not recruiting
NCT06599463 — Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric · completed
NCT06660147 — Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer · recruiting
NCT05364905 — Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Ca · completed
NCT04256213 — COL Immunotherapy Before Radiochimio + Ipilimumab · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02163720 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ARCAGY/ GINECO GROUP
Last refreshed: 28 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02163720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing